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Abstract
Background: Two common single nucleotide polymorphisms within the COL5A1 gene (SNPs; rs12722 C/T and
rs3196378 C/A) have previously been associated with tendon and ligament pathologies. Given the high incidence
of tendon and ligament injuries in elite rugby athletes, we hypothesised that both SNPs would be associated with
career success.
Results: In 1105 participants (RugbyGene project), comprising 460 elite rugby union (RU), 88 elite rugby league
athletes and 565 non-athlete controls, DNA was collected and genotyped for the COL5A1 rs12722 and rs3196378
variants using real-time PCR. For rs12722, the injury-protective CC genotype and C allele were more common in all
athletes (21% and 47%, respectively) and RU athletes (22% and 48%) than in controls (16% and 41%, P ≤ 0.01). For
rs3196378, the CC genotype and C allele were overrepresented in all athletes (23% and 48%) and RU athletes (24%
and 49%) compared with controls (16% and 41%, P ≤ 0.02). The CC genotype in particular was overrepresented in
the back and centres (24%) compared with controls, with more than twice the odds (OR = 2.25, P = 0.006) of
possessing the injury-protective CC genotype. Furthermore, when considering both SNPs simultaneously, the
CC–CC SNP-SNP combination and C–C inferred allele combination were higher in all the athlete groups (≥18% and
≥43%) compared with controls (13% and 40%; P = 0.01). However, no genotype differences were identified for
either SNP when RU playing positions were compared directly with each other.
Conclusion: It appears that the C alleles, CC genotypes and resulting combinations of both rs12722 and rs3196378
are beneficial for rugby athletes to achieve elite status and carriage of these variants may impart an inherited
resistance against soft tissue injury, despite exposure to the high-risk environment of elite rugby. These data have
implications for the management of inter-individual differences in injury risk amongst elite athletes.
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Background
Elite rugby athletes regularly experience high velocity col-
lisions that lead to increasingly high injury occurrence
rates that are likely to be a consequence of the increasing
size and strength of the athletes [1–4]. This increased size
and strength is likely to result in greater changes in mo-
mentum during player collisions, as well as during volun-
tary accelerations and decelerations. This has resulted in
rugby union (RU) having one of the highest reported in-
jury incidence rates in professional team sports [5]. Meta-
analyses have shown that for every 1000 h, an elite RU
athlete will experience approximately 81 injuries during
match play and three during training, with the majority
being ligament, tendon and muscle injuries of the lower
limbs [6]. Indeed, in the most recent Rugby World Cup
(2015) this rate of incidence was more than 90 injuries per
1000 h [7]. Furthermore, pooled data from 10 studies of
elite rugby league (RL) athletes show that injury incidence
is approximately twice (172 per 1000 h) that of RU [8].
Similar to RU, the majority of injuries in RL occur on the
lower limbs, consisting mainly of sprains and strains [8].
Injury incidence differs across RU playing position, with
elite back row players showing the highest rate among for-
wards and centres the highest among backs [7]. Therefore,
investigating the molecular genetic components of these
injuries, including in the context of playing positions that
differ in terms of physiological characteristics [9, 10],
match play demands [11] as well as genetically [12], may
progress understanding towards greater individualisation
of match play exposure and training load and mode, in
order to reduce injury risk [13].
The collagen fibril, which consists predominately of
type I collagen, is the primary structural component of
tendons, ligaments and other non-cartilaginous connect-
ive tissues [14]. The formation and diameter of the colla-
gen fibril is regulated by, amongst other molecules, the
minor fibrillar type V collagen protein [15–18]. The type
V collagen isoform comprises two α1(V) and one α2(V)
chains, encoded by the COL5A1 and COL5A2 genes re-
spectively [16, 19] and forms between 1 and 5% of total
collagen content [18, 20]. The COL5A1 gene is the most
explored genetic locus in relation to tendon and liga-
ment injuries [21–25], while mutations in the COL5A1
gene have been identified in Ehlers-Danlos syndrome, a
disease characterised by joint hypermobility, laxity and
muscle hypotonia [26]. This results in irregularly large
collagen fibrils within connective tissue [27] and is at-
tributed to a reduced synthesis of collagen type V
[17, 28].
Two common single nucleotide polymorphisms (SNPs,
rs12722 C/T and rs3196378 C/A) located in the func-
tional 3′ untranslated region (3′ UTR) COL5A1 gene on
chromosome 9 have been associated with tendon [23]
and ligament ([rs12722] [29]) injuries. Specifically, the
CC genotype of the more extensively investigated
rs12722 polymorphism has been previously associated
with reduced risk of chronic Achilles tendinopathy (odds
ratio (OR) = 0.42-AUS and OR = 0.38-SA, respectively;
[23, 25]), anterior cruciate ligament injury in females
(OR = 6.6; [22]) and lateral epicondylitis (OR = 1.4;
[21]), suggesting a protective role of the C allele against
injury. Although there are conflicting results [23, 30],
our current understanding also suggests that the CC
genotype and/or the C allele of rs3196378 would also
have a protective role [31, 32]. Considering the high fre-
quencies of tendon and ligament inquiries in elite rugby
[6–8, 33], assessing these specific genetic variants may
be of use in helping improve the management of injury
risk in individual players.
Given the association of the two COL5A1 gene vari-
ants with injury risk, it is possible that possession of
the risk alleles might reduce an individual’s ability to
withstand exposure to the environment of competitive
rugby without suffering more frequent injuries. Conse-
quently, those individuals would be forced to miss
training, selection and competitive events important
for their career progression. Thus, athletes carrying
the C allele at either or both rs12722 and rs3196378
might be at an advantage in terms of their ability to
achieve success in elite competitive rugby and at a dis-
advantage in terms of their shorter-term and longer-
term musculoskeletal health. Therefore, the objective
of the present study was to investigate if COL5A1
rs12722 and rs3196378 genotype and allele frequencies
differed between elite rugby athletes and a control
population, and/or between playing positions. It was
hypothesised that the COL5A1 rs12722 and rs3196378
injury-protective C alleles and/or CC genotypes would
be overrepresented in elite rugby athletes compared
with controls.
Methods
Participants
As part of the ongoing RugbyGene project [12, 13, 34], a
total of 1105 individuals were recruited and gave written
informed consent to participate in the present study. An
a priori calculation for 80% power to detect a small
effect size (w) of 0.1 required a sample of >785 partici-
pants. The sample comprised elite Caucasian male rugby
athletes (n = 540; mean (standard deviation) height 1.85
(0.07) m, mass 101 (14) kg, age 29 (7) years) including
72% British, 16% South African, 7% Irish and 5% of
other nationalities. Caucasian controls (68% male;
n = 565; height 1.75 (0.10) m, mass 75 (13) kg, age 26
(11) years) included 86% British, 12% South African, 1%
Irish and 1% of other nationalities recruited mainly dur-
ing 2012–2016. Eight athletes competed in both elite RL
and RU and were included in both groups that were
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analysed separately. Athletes were considered elite if
they had competed regularly (> 5 matches) since 1995 in
the highest professional league in the UK, Ireland or
South Africa for RU and the highest professional league
in the UK for RL. Of the RU athletes, 51.7% had com-
peted at international level for a “High Performance
Union” (Regulation 16, worldrugby.org) and 43.2% of RL
had competed at international level. All data for the ath-
lete group’s international status were confirmed as of 1st
January 2017. Most participants in the current study
were also participants in previous publications regarding
variations in the ACTN3, ACE and FTO genes [12, 34].
Sample collection and genotyping
Description of all molecular procedures have previously
been described in detail [12]. Briefly, blood (~70% of all
samples), saliva (~25%) or buccal swab samples (~5%)
were obtained via the following protocols. Blood from a
superficial forearm vein was put into an EDTA tube and
stored in sterile tubes at −20 °C until processing. Saliva
samples were collected using Oragene DNA OG-500
collection tubes (DNA Genotek Inc., Ontario, Canada)
according to the manufacturer’s protocol and stored at
room temperature until processing. Sterile buccal swabs
(Omni swab, Whatman, Springfield Mill, UK) were
rubbed against the buccal mucosa of the cheek for ap-
proximately 30 s and the tips stored at −20 °C until pro-
cessing. At MMU and Glasgow, DNA was stored at 4 °C
following isolation performed using the QIAamp DNA
Blood Mini kit and standard spin column protocol (Qia-
gen, West Sussex, UK). In Cape Town, DNA was iso-
lated from whole blood [35] and samples stored at −20 °
C. At Northampton, DNA was isolated from whole
blood using Flexigene kits (Qiagen), with the resulting
samples stored at −20 °C.
Genotyping at all three centres was performed using
TaqMan assays (Applied Biosystems, Paisley, UK) for both
the COL5A1 rs12722 and rs3196378 variants. Our geno-
typing methods and quality control procedures have been
fully described in our earlier study [12]. Minor adaptations
were made to the volumes used in each assay mix depend-
ing on whether the DNA was obtained from buccal swabs
or saliva/blood. PCR was performed on either a Chromo4
(Bio-Rad, Hertfordshire, UK) or StepOnePlus thermal cy-
cler (Applied Biosystems). Genotypes were called based
on reporter dye intensity and visualized using cluster
plots. The TaqMan assays included VIC and FAM dyes
that for rs12722 indicated C and T alleles on the forward
DNA strand, respectively. Thus, VIC/FAM were inter-
preted as: 5′-CACACCCA[C/T]GCGCCCCG-3′. For
rs3196378, VIC and FAM dyes indicated C and A alleles
on the forward DNA strand, respectively and were inter-
preted as: 5′-CCCACCCC[A/C]GCCCTGGC-3′. Geno-
type calling was 100% successful for both polymorphisms
in the athlete samples. For rs12722, one of the 566 control
samples was unsuccessful and, for rs3196378, 10 of the
566 control samples were unsuccessful. There was 100%
agreement among reference samples genotyped in the
three genotyping centres, i.e. Glasgow, Northampton and
MMU laboratories.
Data analysis
SPSS for Windows version 22 (SPSS Inc., Chicago, IL)
software was used to conduct Pearson’s Chi-square (χ2)
tests to compare genotype (using three analysis models;
additive, recessive and dominant), allele and inferred
haplotype frequencies between athletes and controls, and
between RU subgroups based on playing position and
controls. With 80% statistical power, analyses of all genetic
models in positional subgroups compared with controls
(forwards, backs and back 3-centres) were able to detect a
small-to-medium effect size (w) of 0.12. Multifactor
Dimensionality Reduction (MDR; www.multifactordimen-
sionalityreduction.org) software was used to calculate
SNP-SNP epistasis interactions [36]. Haplotypes were in-
ferred using SNPStats [37]. Sixty five tests were subjected
to Benjamini-Hochberg (BH; [38]) corrections to control
false discovery rate and corrected probability values are
reported. Odds ratios (OR) were calculated to estimate
effect size. CubeX online software (www.oege.org/soft-
ware/cubex) was used to determine linkage disequilibrium
statistics [39]. Alpha was set at 0.05.
Results
Genotype frequencies were in Hardy-Weinberg equilib-
rium for both rs12722 and rs3196378 in the control
(P ≥ 0.21) and athlete groups (RL, P ≥ 0.11; RU,
P ≥ 0.754). There was no sexual dimorphism of genotype
frequency for either rs12722 (P = 0.279) or rs3196378
(P = 0.374) within the control group. COL5A1 rs12722
and rs3196378 were in tight linkage disequilibrium for
both controls (D′ = 0.902, r2 = 0.784) and all athletes (D
′ = 0.877, r2 = 0.738). Athletes were taller and heavier
(P < 0.05) but not older (P > 0.05) than controls.
rs12722
The CC genotype, proportion of C allele carriers and C
allele were overrepresented in all athletes (21.1%, 73.3%
and 47.2%, respectively) and RU athletes (22.0%, 73.3%
and 47.6%) compared with controls (15.6%, 66.5% and
41.1%, Table 1 and Fig. 1, P ≤ 0.01). Furthermore, the
CC genotype, proportion of C allele carriers (Table 1)
and C allele (Fig. 1) were overrepresented in the sub-
groups of RU forwards (22.1%, 71.5% and 46.8%) and
backs (21.8%, 75.6% and 48.7%) compared with controls
(15.6%, 66.5% and 41.1%). Additionally, of the RU sub-
groups, the back three and centres differed from con-
trols and showed the greatest C allele and CC genotype
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frequency (50.8% versus 41.1% and 24.4% versus 15.6%,
respectively, Table 1 and Fig. 1, P ≤ 0.02). Compared
with controls, those back three and centre players had
2.3 times the odds of possessing the CC genotype and
1.5 times the odds of possessing the C allele (Table 2).
rs3196378
The CC genotype, proportion of C allele carriers and C al-
lele were overrepresented in all athletes (23.1%, 73.3% and
48.4%) and RU athletes (23.9%, 73.3% and 48.6%) com-
pared with controls (15.6%, 67.7% and 41.4%, Table 1 and
Table 1 COL5A1 rs12722 and rs3196378 genotype and allele distribution of controls and athletes separated by code (RL and RU)
and into positional sub-groups for RU, presented as genotype/allele counts followed by percentage in parentheses
Genotype Controls All athletes RL athletes RU athletes Forwards Backs Back 3 and Centres
rs12722
TT 189 (33.4) 144 (26.7) 23 (26.1) 123 (26.7) 75 (28.5) 48 (24.4) 28 (22.8)
CT 288 (51.0) 282 (52.2) 51 (58.0) 236 (51.3) 130 (49.4) 106 (53.8) 65 (52.8)
CC 88 (15.6) 111 (21.1)* 14 (15.9) 101 (22.0)* 58 (22.1)* 43 (21.8)* 30 (24.4)*
Total 565 540 88 460 263 197 123
T allele carriers 477 (84.4) 426 (78.9)* 74 (84.1) 359 (78.0)* 205 (77.9)* 154 (78.2)* 93 (75.6)*
C allele carriers 379 (66.5) 396 (73.3)* 65 (73.9) 337 (73.3)* 188 (71.5) 149 (75.6)* 95 (77.2)*
rs3196378
AA 183 (32.9) 144 (26.7) 23 (26.1) 123 (26.7) 74 (28.1) 49 (24.9) 28 (22.8)
CA 286 (51.4) 271 (50.2) 49 (55.7) 227 (49.3) 122 (46.4) 105 (53.3) 65 (52.8)
CC 87 (15.6) 125 (23.1)* 16 (18.2) 110 (24.0)* 67 (25.5)* 43 (21.8) * 30 (24.4)*
Total 556 540 88 460 263 197 123
A allele carriers 469 (84.4) 415 (76.9)* 72 (81.8) 350 (76.1)* 196 (74.5)* 154 (78.2)* 93 (75.6)*
C allele carriers 373 (67.1) 396 (73.3)* 65 (73.9) 337 (73.3)* 189 (71.9) 148 (75.1)* 95 (77.2)*
RU, rugby union, RL rugby league. The genotype, T allele carrier and C allele carrier data represent the additive, dominant model and recessive models,
respectively. Eight athletes competed in both elite RL and RU and were included in both groups that were analysed separately
Asterisks (*) indicate Chi-square differences from controls (P ≤ 0.03)
Fig. 1 Allele frequency of COL5A1 rs12722 (a) and rs3196378 (b) for control and athlete groups. Asterisks indicate a difference in allele frequency
between the particular athlete group and controls. A single asterisk (*) designates P = 0.01 and a double asterisk (**) designates P = 0.02. RU,
rugby union, RL rugby league. Eight athletes competed in both elite RL and RU and were included in both groups that were analysed separately
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Fig. 1, P ≤ 0.02). Furthermore, CC genotype, proportion of
C allele carriers (Table 1) and C allele (Fig. 1) were over-
represented in backs (21.8%, 75.1% and 48.5%) compared
with controls (15.6%, 67.7% and 41.4%, P ≤ 0.02). For-
wards also had higher CC genotype and C allele frequen-
cies (25.5% and 48.7%; Table 1 and Fig. 1) and showed
almost twice the odds of being CC genotype than carrying
an A allele, compared with controls (Table 2). For the back
three and centres group, 24.4% were CC genotype, 77.2%
were C allele carriers and C allele frequency was 47.8% -
all of which were greater than controls (P ≤ 0.02; Table 1
and Fig. 1, OR = 2.25, Table 2).
Haplotype and SNP epistasis analysis
There was a greater frequency of the CC–CC SNP-SNP
combination in all athletes (18.3%), RU athletes (18.9%),
RU forwards (19.4%), RU backs (18.3%) and to the great-
est extent the back three and centre group (20.3%;
Table 2 Odds ratio statistics for RU player status of COL5A1 gene variants (rs12722 and rs3196378)
Positional comparison Model bOdds Ratio 95% Confidence Interval
rs12722
All athletes v Controls CC/TT
CC/Tcarriers
Callele/Tallele
1.70
1.45
1.28
1.19–2.42
1.07–1.97
1.08–1.52
RU athletes v Controls CC/TT
CC/Tcarriers
Callele/Tallele
1.76
1.53
1.30
1.22–2.54
1.11–2.09
1.09–1.55
Forwards v Controls CC/TT
CC/Tcarriers
Callele/Tallele
1.66
1.53
1.26
1.08–2.54
1.06–2.22
1.02–1.55
Backs v Controls CC/TT
CC/Tcarriers
Callele/Tallele
1.92
1.51
1.36
1.19–3.12
1.01–2.27
1.08–1.72
Back 3 and centres v Controls CC/TT
CC/Tcarriers
Callele/Tallele
2.30
1.76
1.48
1.29–4.08
1.09–2.78
1.12–1.96
rs3196378
All athletes v Controls CC/AA
CC/Acarriers
Callele/Aallele
1.83
1.66
1.32
1.29–2.59
1.22–2.25
1.12–1.56
RU athletes v Controls CC/AA
CC/Acarriers
Callele/Aallele
1.88
1.73
1.34
1.31–2.70
1.27–2.37
1.12–1.59
Forwards v Controls CC/AA
CC/Acarriers
Callele/Aallele
1.90
1.88
1.34
1.25–2.89
1.31–2.69
1.09–1.66
Backs v Controls CC/AA
CC/Acarriers
Callele/Aallele
1.85
1.54
1.33
1.14–2.99
1.02–2.31
1.06–1.68
Back 3 and centres v Controls CC/AA
CC/Acarriers
Callele/Aallele
2.25
1.78
1.46
1.27–4.00
1.11–2.84
1.11–1.93
Haplotypes and SNP epistasis
All athletes v Controls C–C/T–A
aCC–CC
1.31
1.97
1.10–1.56
1.44–2.69
RU athletes v Controls C–C/T–A
aCC–CC
1.32
2.11
1.11–1.59
1.53–2.91
Forwards v Controls C–C/T–A
aCC–CC
1.31
2.19
1.05–1.62
1.51–3.16
Backs v Controls C–C/T–A
aCC–CC
1.36
1.86
1.07–1.72
1.29–2.67
Back 3 and centres v Controls C–C/T–A
aCC–CC
1.49
2.35
1.12–1.99
1.47–3.77
aMDR best model versus all other genotype combinations for rs12722 and rs3196378
bAll odds ratios were statistically significant (P < 0.05)
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OR = 2.35; Table 2), compared with control (12.8%; all
athlete comparisons with the control group were
P = 0.01). Furthermore, C–C inferred haplotype frequen-
cies were higher in all the athlete groups compared with
controls, reflected by a greater frequency of the T–A in-
ferred haplotype in the control group (P = 0.01; Fig. 2).
Discussion
The present observations are the first to identify associa-
tions between COL5A1 rs12722 and rs3196378 polymor-
phisms and athlete status in a large cohort of elite rugby
athletes. As hypothesised, the apparent injury-protective
C allele and CC genotype, of both SNPs [23], were over-
represented in elite rugby athletes compared with con-
trols. This association persisted across playing position,
with the C allele being overrepresented in RU forwards
and backs including the back three and centres group,
compared with controls. Furthermore, when the two
SNPs are combined, the CC–CC combination and C–C
inferred allele combination showed similar overrepresen-
tation in elite rugby athletes compared with controls.
The results provide an insight into the potential injury
susceptibility of some elite rugby athletes. September et
al. [23] identified a higher frequency of the CC genotype
in asymptomatic controls for both rs12722 and
rs3196378 compared with tendinopathy patients [23,
32]. Moreover, the rs12722 T allele has been associated
with ligament injury [21, 22, 24, 40] and Achilles tendi-
nopathy [23, 25] with the C allele again identified as pro-
tective in these studies, despite a lack of replication in
another study [30]. Greater joint laxity has almost a 3-
fold increase in risk of knee ligament rupture [41] and
greater joint laxity has recently been associated with the
rs12722 T allele in non-white females [40]. Collectively,
these data suggest that the C allele of rs12722 and/or
rs3196378 (or other variant(s) in strong LD with these
SNPs) might be beneficial in protecting against tendon
and ligament injuries. This is reflected in the present
study showing greater C allele frequency in elite rugby
athletes compared with controls. Based on these data,
we propose that when exposed to the high-risk environ-
ment of rugby during training and especially during
competitive matches, ceteris paribus, carriage of the C
alleles at the rs12722 and rs3196378 loci provides both a
shorter-term and longer-term advantage to rugby ath-
letes in the form of reduced injury risk. Athletes with
fewer and/or less severe injuries, all else being equal, will
miss fewer matches, training and selection events and
thus be more likely to progress towards elite status in
their athletic careers compared with their peers.
The rs12722 CC genotype has also been related to a
lower incidence of exercise-associated muscle cramping
(EAMC) in Caucasian ironman and ultra-marathon ath-
letes [42]. The authors hypothesised that this was due to
similar mechanisms of reduced tendon injury suscepti-
bility, in that rs12722 alters soft tissue structural and
mechanical properties (tissue stiffness and thickening).
Some recent findings might support this hypothesis, as
greater tendon stiffness was associated with the rs12722
T allele in one study [43], however another study re-
ported no association of rs12722 with tendon structural
or mechanical properties [44]. These data suggest that in
addition to the apparent protection from tendon and
ligament injury, the greater frequencies of the C allele in
elite rugby athletes might be protective against muscle
cramping and possibly reduced tendon stiffness. Indeed,
recent evidence from elite RL shows that over 70% of
athletes experience EAMC per season and that history
of cramping is the strongest predictor of future EAMC
[45]. In contrast, the TT genotype has been associated
Fig. 2 Inferred haplotype frequencies derived from COL5A1 rs12722 and rs3196378. RU, rugby union. Asterisks (*) indicate differences in inferred
haplotype frequencies between the controls and each athlete group (P = 0.01). Eight athletes competed in both elite RL and RU and were
included in both groups that were analysed separately
The Author(s) BMC Genomics 2017, 18(Suppl 8):820 Page 34 of 131
with greater endurance running ability of Caucasian
ironman triathletes (TT = 294 min, CC = 307 min; [46]).
However, recent data show no association of rs12722
with either running economy or V 2max [47]. While en-
durance capacity is of value in elite rugby, the predom-
inant focus of player selection and training programs is
towards power, speed and strength - i.e. short-term, an-
aerobic performance [with notable differences between
playing positions; 9, 10].
Limited data exist regarding COL5A1 genetic variation
and team sport athletes. In a study of 73 soccer athletes,
including some elite players, no rs12722 TT genotype in-
dividuals were identified (a potentially interesting obser-
vation but difficult to interpret because of the varied
geographic ancestry of the athletes), but there was a ten-
dency for more severe muscle injuries in the TC geno-
type group (P = 0.08), compared with CC [48]. Here,
consistent with those observations, we show an overrep-
resentation of the protective C allele and CC genotype
of both rs12722 and rs3196378, in addition to CC–CC
SNP-SNP combination and C–C inferred allele combin-
ation in elite rugby athletes.
Some possible mechanisms have been proposed to
explain the association of COL5A1 gene variants and
soft tissue injury [31, 32]. Laguett et al. [32] have
shown that the COL5A1 3′ UTR – where both
rs12722 and rs3196378 are situated - affects mRNA
stability. For both SNPs, the alleles associated with
greater soft-tissue injury risk were associated with
greater Hsa-miR-608 stability, which in turn may alter
the Col5α1 protein secondary structure - proposed to
play a role in type V collagen production [31]. This
would suggest that C/T allele differences at rs12722
might alter the co-polymerisation of collagen type V
and type I fibrils. However, to date, this has not been
demonstrated experimentally and exactly how this
may translate into functional properties is currently
unknown. Nevertheless, it appears that the C allele
and CC genotype of rs12722 and rs3196378 appear
beneficial for rugby athletes to achieve elite status,
probably through greater resistance to soft tissue in-
jury. Interestingly, while most relevant investigations
have focussed on rs12722, we show in a large cohort
(total n = 1090) that strong linkage disequilibrium
exists in both controls and athletes between rs12722
and rs3196378. As such, it is likely that the associa-
tions of rs12722 with tendon and ligament injuries
would be similar for rs3196378. It is possible that
combining genetic data from multiple gene variants
associated with injury susceptibility, such as those
presented here, with other indicators of injury risk
and recovery during rehabilitation could be used to
better manage the prevention and recovery from elite
player injury in the future.
Conclusion
In conclusion, we have presented the first associations
between COL5A1 3′ UTR rs12722 and rs3196378 and
elite status within a large cohort of rugby athletes. The
C alleles of both polymorphisms, separately and in com-
bination, were overrepresented in all athletes, RU for-
wards, backs and in RU back three and centre players
versus controls. We propose that rugby athletes posses-
sing more C alleles at these two genetic loci are probably
at a lower risk of injury, given their exposure to the
high-risk environment of elite rugby. However, these
data pertain to only two SNPs of many that may be rele-
vant to soft tissue injury and interpretation of the
present results should be in that context. Future investi-
gations should seek to combine elite rugby genotype
data such as these with injury incidence data during
rugby matches and training. It will be important to es-
tablish whether inter-individual differences in injury risk,
within a population that we demonstrate here appear to
be at an overall lower genetic risk of tendon and liga-
ment injury compared with non-athletes, nevertheless
are associated with those same genetic loci.
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